Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Jul 22, 2022 2:39pm

125 Views

Post# 34844069

My opinion

is as soon as john is done selling i believe the stock will bounce back up to the mid 70,s. clearly no one else is interested in selling. and any buying is met with johns selling therefor we are momentarily stuck in this tight trading range. that is why i have been slowly adding @60 cents and lower what i call my trading shares because i plan to dump them when the stock bounces back. but plan to keep my core position. i think it is a good time to load up for when that day back to the 70's comes. there is some free trading advice for davgro i know he needs it.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property